Memory and Mitochondria: Are We Entering the Era of Programmable Brain Energy?

Memory and Mitochondria: Are We Entering the Era of Programmable Brain Energy?

Scientists remotely reactivated mitochondrial signaling and restored memory in dementia models, introducing a new paradigm for neurodegenerative therapy.

A new study published in Nature Neuroscience, led by Giovanni Marsicano and Luigi Bellocchio from NeuroCentre Magendie, INSERM and University of Bordeaux, together with Étienne Hébert-Chatelain from Université de Moncton, introduces a major conceptual shift in neurodegeneration research: instead of attempting only to protect damaged neurons, researchers directly reactivated mitochondrial signaling to restore brain function.

The work describes an engineered system called mitoDREADD-Gs, designed to selectively stimulate signaling pathways inside mitochondria.

Mitochondria generate ATP through oxidative phosphorylation. In neurons, this function is critical because synaptic transmission and memory formation require continuous energy. In Alzheimer’s disease and other neurodegenerative disorders, mitochondrial dysfunction, loss of membrane potential, impaired respiration, and metabolic failure are commonly observed.

To test whether restoring mitochondrial activity could directly improve cognition, the researchers engineered a synthetic GPCR-based receptor targeted to mitochondria. The system uses DREADD technology, meaning Designer Receptors Exclusively Activated by Designer Drugs, allowing mitochondrial signaling to be remotely activated using a synthetic ligand.

The receptor was fused to a mitochondrial targeting sequence and localized primarily to the outer mitochondrial membrane. Once activated, it stimulated mitochondrial Gs signaling, leading to increased cyclic AMP-associated pathways inside the organelle.

The consequences were significant:

• Increased mitochondrial membrane potential, Δψm
• Enhanced oxygen consumption rate, OCR
• Improved mitochondrial respiration
• Restoration of synaptic plasticity
• Recovery of memory performance in mouse models

Importantly, the intervention improved cognition not only in pharmacologically induced memory impairment, but also in mouse models of Alzheimer’s disease and frontotemporal dementia.

The study suggests that mitochondrial dysfunction may not simply be a downstream consequence of neurodegeneration, but an active driver of cognitive decline that can potentially be therapeutically reversed.

Scientifically, the work expands the emerging field of organelle-targeted signaling, where intracellular organelles are treated as programmable therapeutic platforms rather than passive structures.

This marks a departure from conventional mitochondrial medicine approaches centered mainly on antioxidants or damage prevention. Instead, the study proposes a new framework:

Mitochondria may become controllable bioenergetic hubs capable of dynamically modulating neuronal function.

This work raises a deeper question for neuroscience and mitochondrial medicine: if mitochondria can be remotely reactivated, are we still looking at dementia as a problem of irreversible neuronal loss, or as a failure of cellular energy control that may be corrected?

At the World Mitochondria Society, this strategic shift will be discussed through key questions:

Can cognitive decline be reversed by restoring mitochondrial bioenergetics before neurons are lost?

Are mitochondria becoming the next therapeutic control point in Alzheimer’s disease and dementia?

Although the work remains preclinical and was performed in mice, it opens new perspectives for mitochondrial neuromodulation, programmable bioenergetics, and future strategies aimed at restoring cognition through direct mitochondrial reactivation.

Read the complete news here

Read the news on LinkedIn